Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 10/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157826 | 0.90 | KDM1A (0.48) | KDM1AMAOASLC22A12CNR1IDH1 | |
| SCHEMBL2157434 | 0.88 | SLC22A12 (0.51) | KDM1AMAOASLC22A12ALDH1A1TP53 | |
| SCHEMBL2157668 | 0.88 | HSD17B2 (0.49) | KDM1AMAOASLC22A12ALDH1A1TP53 | |
| SCHEMBL2157786 | 0.88 | KDM1A (0.45) | KDM1AMAOASLC22A12ALDH1A1TP53 | |
| SCHEMBL2158359 | 0.88 | MAPT (0.45) | KDM1AMAOASLC22A12IDH1ALDH1A1 | |
| SCHEMBL2157624 | 0.86 | CNR1 (0.49) | KDM1AMAOACNR1IDH1 | |
| SCHEMBL12464422 | 0.86 | ALDH1A1 (0.54) | KDM1AMAOASLC22A12ALDH1A1TP53 | |
| SCHEMBL2157859 | 0.85 | TP53 (0.44) | KDM1AMAOAIDH1ALDH1A1TP53 | |
| SCHEMBL2158575 | 0.85 | LMNA (0.50) | KDM1AMAOAALDH1A1TP53 | |
| SCHEMBL2157735 | 0.85 | SLC22A12 (0.46) | KDM1AMAOASLC22A12IDH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | KDM1A 2573/4885MAOA 1048/4885SLC22A12 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.